9th Jun 2020 08:46
(Alliance News) - The UK Competition & Markets Authority on Tuesday said it has decided against an in-depth probe of Dechra Pharmaceuticals PLC's proposed acquisition of the Osurnia business of Elanco Animal Health Inc.
The watchdog started its preliminary probe into the deal in March.
Dechra, a veterinary pharmaceuticals firm based in Northwich, Cheshire, had said in January it would be buying Osurnia off Elanco for USD135 million. Osurnia is a treatment for ear infections in dogs.
Shares in Dechra were up 0.6% at 2,856.00 pence each in London on Tuesday morning.
By Tapan Panchal; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
DPH.L